Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4481-4490

  Shane, Elizabeth ^a   Cohen, Adi ^a   Stein, Emily M ^a   McMahon, Donald J ^a   Zhang, Chiyuan ^a   Young, Polly ^a   Pandit, Kavita ^a   Staron, Ronald B ^a   Verna, Elizabeth C ^a   Brown, Robert ^a   Restaino, Susan ^a   Mancini, Donna ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; PARATHYROID HORMONE; PLACEBO; PREDNISONE; TACROLIMUS; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FEMUR NECK; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART TRANSPLANTATION; HIP; HUMAN; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VITAMIN BLOOD LEVEL;

ADULT; ALENDRONATE; ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HEART TRANSPLANTATION; HUMANS; IMIDAZOLES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PLACEBOS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 84870756970     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2804     Document Type: Article

References (37)

1. Cohen A, Ebeling P, Sprague S, Shane E 2006 Transplantation osteoporosis. In: Favus M, ed. Primer on the metabolic bone diseases and disorders of bone and mineral metabolism. Washington, DC: American Society for Bone and Mineral Research; 302-309
2. Cohen A, Shane E 2003 Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14:617-630 (Pubitemid 41490345)
3. Compston JE 2003 Osteoporosis after liver transplantation. Liver Transpl 9:321-330 (Pubitemid 36443042)
4. Stein E, Compston J, Shane E 2009 Transplantation osteoporosis. In: Bilezikian JP, ed. Osteoporosis in men. London: Elsevier; 443-452
5. Stein E, Ebeling P, Shane E 2007 Post-transplantation osteoporosis. Endocrinol Metab Clin North Am 36:937-963; viii
6. Guichelaar MM, Schmoll J, Malinchoc M, Hay JE 2007 Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatol 46:1198-1207 (Pubitemid 350144784)
7. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R 2001 Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 357:342-347 (Pubitemid 32128540)
8. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D 2004 Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767-776 (Pubitemid 38209646)
9. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW 2006 Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239-248 (Pubitemid 46768206)
10. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H 2003 Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669-2676 (Pubitemid 37169355)
11. De Sévaux RG, Hoitsma AJ, Corstens FH, Wetzels JF 2002 Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 13:1608-1614 (Pubitemid 34579249)
12. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer- Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H 2009 Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335-1344
13. Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC 2001 Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12:1530-1537 (Pubitemid 32666337)
14. Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, Cockwell P, Sweny P, Banks LM, Hall-Craggs M, Noonan K, Andrews C, Cunningham J 2009 Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis 53:856-865
15. Stein EM, Ortiz D, Jin Z, McMahon DJ, Shane E 2011 Prevention of fractures after solid organ transplantation: a meta-analysis. J Clin Endocrinol Metab 96:3457-3465
16. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
17. Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR 2010 Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res 25:2251-2255
18. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253-1263
19. Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings SR 1995 Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res 10:890-902
20. Black DM, Palermo L, Nevitt MC, Genant HK, Christensen L, Cummings SR 1999 Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:90-101 (Pubitemid 29021608)
21. Ebeling PR 2009 Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab 94:1483-1490
22. Sambrook PN, Kelly PJ, Fontana D, Nguyen T, Keogh A, Macdonald P, Spratt P, Freund J, Eisman JA 1994 Mechanisms of rapid bone loss following cardiac transplantation. Osteoporos Int 4:273-276 (Pubitemid 24291435)
23. Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ, Mancini D, Michler RE, Aaronson K, Addesso V, Lo SH 1997 Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 82:1497-1506 (Pubitemid 27200425)
24. Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martinez de Osaba MJ, Ordi J, Rimola A, Rodés J, Muñoz-Gómez J 2001 Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484-492 (Pubitemid 32607092)
25. Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martínez de Osaba MJ, Rimola A, Rodés J, Muñoz-Gómez J 2001 Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 68:83-86 (Pubitemid 32289863)
26. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid- induced osteoporosis. N Engl J Med 337:382-387 (Pubitemid 27328368)
27. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA1999 Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42:2309-2318
28. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299 (Pubitemid 28366417)
29. Atamaz F, Hepguler S, Karasu Z, Kilic M, Tokat Y 2006 The prevention of bone fractures after liver transplantation: experience with alendronate treatment. Transplant Proc 38:1448-1452
30. Abediazar S, Nakhjavani MR 2011 Effect of alendronate on early bone loss of renal transplant recipients. Transplant Proc 43:565-567
31. Trabulus S, Altiparmak MR, Apaydin S, Serdengecti K, Sariyar M 2008 Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplant Proc 40:160-166 (Pubitemid 351186668)
32. Lan G, Peng L, Xie X, Peng F, Wang Y, Yu S 2008 Alendronate is effective to treat bone loss in renal transplantation recipients. Transplant Proc 40:3496-3498
33. Bodingbauer M, Wekerle T, Pakrah B, Roschger P, Peck-Radosavljevic M, Silberhumer G, Grampp S, Rockenschaub S, Berlakovich G, Steininger R, Klaushofer K, Oberbauer R, Mühlbacher F 2007 Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 7:1763-1769 (Pubitemid 46905434)
34. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM 2003 Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349:931-940 (Pubitemid 37064766)
35. Verna EC, Farrand ED, Elnaggar AS, Pichardo EM, Balducci A, Emond JC, Guarrera JV, Brown Jr RS 2011 Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplantation 91:1254-1260
36. Stein EM, Cohen A, Freeby M, Rogers H, Kokolus S, Scott V, Mancini D, Restaino S, Brown R, McMahon DJ, Shane E 2009 Severe vitamin D deficiency among heart and liver transplant recipients. Clin Transplant 23:861-865
37. Breen TL, Shane E 2004 Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol 22:1531-1532 (Pubitemid 41103642)